William Hildebrand

Dr. Hildebrand earned his PhD from Southern Illinois University in 1990 and conducted post-doctoral research at Stanford University with Dr. Peter Parham. He is a Presbyterian Health Foundation Endowed Professor, a George Lynn Cross Research Professor, and a Presidential Professor in the Department of Microbiology and Immunology at The University of Oklahoma Health Sciences Center. He is President of the American Society for Histocompatibility and Immunogenetics (ASHI) and he serves on the Board of Directors for the United Organ Sharing Network (UNOS) and the Organ Procurement Transplant Network (OPTN). He is an ABHI Diplomate and Director of the OUHSC Clinical HLA Typing Laboratory.

Dr. Hildebrand has been a CLIA-Accredited Clinical HLA Laboratory Director and an American Board for Histocompatibility and Immunogenetics Diplomat since 1998. He has been awarded over $70M in grants from regional and federal government agencies as well as from private corporations. To date, he has authored over 140 publications, reviews, and book chapters in peer-reviewed industry works as well as popular science journals; he was Associate Editor of the Journal of Immunology from 2006-2010 and President of the American Society for Histocompatibility and Immunogenetics in 2020-2021. Dr. Hildebrand has served on editorial, advisory, and national review panel boards including that for the Center for HIV/AIDS Vaccine Immunology (CHAVI), the American Society for Hematology, the National Institute for Allergy and Infectious Diseases, and the National Marrow Donor Program. He has appeared on numerous radio and television news programs and in public service announcements highlighting his research; likewise, he is a frequent invited keynote speaker and advisor to international conferences and private industry companies. Dr. Hildebrand holds 77 patents (issued or pending) in fields related to the discovery and use of the soluble HLA protein technology he has developed.

Dr. Hildebrand and Emergent Technologies, Inc. co-founded Pure Protein, LLC in 1999 where Dr. Hildebrand serves as its Chief Scientist. Later, three additional subsidiary companies were formed, Pure Transplant and Pure Vaccine Solutions in 2003 and Pure MHC in 2013. The “Pure” companies were founded on the principle that a ready source of native HLA proteins can contribute to modulating and understanding autoimmune, transplant, allergy, pathogen, and vaccine-derived immune responses. Pure MHC embodies Dr. William Hildebrand’s vision for the future of MHC research and development by offering breakthrough therapeutic target discovery and validation with further drug and assay development applications.